FIELD: medicine.
SUBSTANCE: present group of inventions relates to new compounds of the formula I
,
their pharmaceutically acceptable salts, as well as to a pharmaceutical composition, a method for inhibition of biological activity of an epidermal growth factor receptor (hereinafter – EGFR), a method for the treatment of diseases or disorders mediated by EGFR activity, and the use of the claimed compounds or the specified composition for the treatment of a disease or a disorder mediated with EGFR activity.
EFFECT: obtaining an inhibitor for an epidermal growth factor receptor.
16 cl, 14 ex, 16 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL HETEROCYCLIC COMPOUNDS AS CDK8/19 INHIBITORS | 2018 |
|
RU2739489C2 |
| EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | 2022 |
|
RU2821531C2 |
| NEW CDK8/19 INHIBITORS | 2019 |
|
RU2754441C2 |
| ACRYLANILIDE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN PHARMACOLOGY | 2016 |
|
RU2742372C2 |
| PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | 2014 |
|
RU2656591C2 |
| EGFR INHIBITOR COMPOUNDS | 2017 |
|
RU2751341C2 |
| 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND | 2015 |
|
RU2704129C2 |
| CERTAIN CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS | 2014 |
|
RU2718876C2 |
| INHIBITOR OF EGFR AND PRODUCTION AND USE THEREOF | 2015 |
|
RU2702631C2 |
| CDK8/19 INHIBITORS | 2018 |
|
RU2761824C2 |
